Other PD-1 inhibitors encompass pembrolizumab (MK-3475, lambrolizumab) and cemiplimab, which respectively exhibit acceptable tolerance and remarkable efficacy in several tumors such as advanced NSCLC and advanced squamous cell carcinoma (SCC) 14. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.